Medicinova (MNOV) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Medicinova (MNOV) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 8.4% versus a loss of 30.8%. Zhengye Biotechnology is the larger company by market cap ($70.1 million vs $67.1 million), about 1.0 times the size. Zhengye Biotechnology converts more of its revenue into profit, with a net margin of -60.0% versus -2928.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | ZYBT |
|---|---|---|
| Share price | $1.31 | $1.48 |
| Market cap | $67.11M | $70.14M |
| 1-day change | +3.15% | -2.63% |
| YTD return | 0.00% | +28.70% |
| 1-year return | -8.39% | -30.84% |
| 5-year return | -59.32% | — |
| EPS (TTM) | $-0.21 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $409.66K | $16.64M |
| Revenue growth (YoY) | — | -34.83% |
| Net income (latest FY) | $-12.00M | $-9.98M |
| Gross margin | — | 20.51% |
| Operating margin | -3242.47% | -60.60% |
| Net margin | -2928.78% | -59.99% |
| 52-week high | $3.90 | $8.01 |
| 52-week low | $1.22 | $0.616 |
| Distance from 52-week high | -66.41% | -81.52% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +529.77% | — |
| Average volume | 334.96K | 569.22K |
| Shares outstanding | 51.23M | 47.39M |
| Employees | 6 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed ZYBT by 22.4 percentage points over the past year.
- Zhengye Biotechnology is more profitable, keeping -60.0 cents of every revenue dollar as net income versus -2928.8 cents for Medicinova.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
MNOV vs ZYBT FAQ
Which is bigger, Medicinova or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $70.14M compared with $67.11M for Medicinova (MNOV).
Which stock has performed better over the past year, MNOV or ZYBT?
MNOV returned -8.39% over the past 12 months, compared with -30.84% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.